海德堡制药公布了强劲的财务业绩，并于 2023 年成功进行了 HDP-101 治疗多发性骨髓瘤的临床试验。 Heidelberg Pharma reports strong financial results and successful clinical trial for HDP-101 in multiple myeloma in 2023.
海德堡制药公布了 2023 年强劲的财务业绩和成功的业务表现，其中包括 HDP-101 多发性骨髓瘤临床试验的疗效数据。 Heidelberg Pharma reports strong financial results and successful business performance in 2023, with efficacy data from the clinical trial of HDP-101 in multiple myeloma. 公司扩大了ADC技术平台，并成功融资，销售收入和其他收入均超过计划。 The company has expanded its ADC technology platform and achieved successful financing activities, resulting in sales revenue and other income above plan. 首席执行官 Andreas Pahl 对 2023 年第一个临床候选药物取得的重大进展发表了评论。 CEO Andreas Pahl comments on the significant progress made with the first clinical candidate in 2023.